{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:28:49Z","timestamp":1775089729295,"version":"3.50.1"},"reference-count":141,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Multiple myeloma and monoclonal gammopathy of undetermined significance are plasma cell dyscrasias characterized by monoclonal proliferation of pathological plasma cells with uncontrolled production of immunoglobulins. Autoimmune pathologies are conditions in which T and B lymphocytes develop a tendency to activate towards self-antigens in the absence of exogenous triggers. The aim of our review is to show the possible correlations between the two pathological aspects. Molecular studies have shown how different cytokines that either cause inflammation or control the immune system play a part in the growth of immunotolerance conditions that make it easier for the development of neoplastic malignancies. Uncontrolled immune activation resulting in chronic inflammation is also known to be at the basis of the evolution toward neoplastic pathologies, as well as multiple myeloma. Another point is the impact that myeloma-specific therapies have on the course of concomitant autoimmune diseases. Indeed, cases have been observed of patients suffering from multiple myeloma treated with daratumumab and bortezomib who also benefited from their autoimmune condition or patients under treatment with immunomodulators in which there has been an arising or worsening of autoimmunity conditions. The role of bone marrow transplantation in the course of concomitant autoimmune diseases remains under analysis.<\/jats:p>","DOI":"10.3390\/diagnostics14111135","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T03:45:08Z","timestamp":1717040708000},"page":"1135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Autoimmune Diseases and Plasma Cells Dyscrasias: Pathogenetic, Molecular and Prognostic Correlations"],"prefix":"10.3390","volume":"14","author":[{"given":"Laura","family":"Giordano","sequence":"first","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1440-2695","authenticated-orcid":false,"given":"Rossella","family":"Cacciola","sequence":"additional","affiliation":[{"name":"Hemostasis\/Hematology Unit, Department of Experimental and Clinical Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Barone","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Vecchio","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elisa","family":"Nasso","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Eugenia","family":"Alvaro","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[{"name":"School and Operative Unit of Allergy and Clinical Immunology, Department and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Cacciola","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences and Advanced Technologies \u201cG.F. Ingrassia\u201d, University of Catania, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-8239","authenticated-orcid":false,"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Human Pathology in Adulthood and Childhood \u201cGaetano Barresi\u201d, University of Messina, Via Consolare Valeria, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"153114","DOI":"10.1016\/j.prp.2020.153114","article-title":"Immune checkpoint inhibitors in multiple myeloma: A review of the literature","volume":"216","author":"Caserta","year":"2020","journal-title":"Pathol. Res. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12288-021-01410-3","article-title":"Multiple Myeloma in Young Adults: A Single Centre Real World Experience","volume":"37","author":"Pydi","year":"2021","journal-title":"Indian. J. Hematol. Blood Transfus."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12253-018-0526-1","article-title":"Multiple Myeloma of the Young\u2014A Single Center Experience Highlights Future Directions","volume":"26","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: Recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","article-title":"From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells","volume":"78","author":"Spaan","year":"2018","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.clml.2023.07.005","article-title":"Multiple Myeloma in Adolescent and Young Adults: An ASCO CancerLinQ and SEER Analysis","volume":"23","author":"Gibson","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","article-title":"Pathobiology and Diagnosis of Multiple Myeloma","volume":"33","author":"Brigle","year":"2017","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/1756-185X.12267","article-title":"A case series of autoimmune diseases accompanied by incidentally diagnosed monoclonal gammopathy: Is there a link between the two diseases?","volume":"17","author":"Cho","year":"2014","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3816\/CLM.2008.n.033","article-title":"Familial multiple myeloma associated with disorders of chronic inflammation: First report from Turkey","volume":"8","author":"Ozet","year":"2008","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.beha.2005.01.013","article-title":"Renal, hematologic and infectious complications in multiple myeloma","volume":"18","year":"2005","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.blre.2019.01.001","article-title":"Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations","volume":"34","author":"Girmenia","year":"2019","journal-title":"Blood Rev."},{"key":"ref_15","first-page":"251","article-title":"Powik\u0142aniainfekcyjne w przebieguszpiczakaplazmocytowego [Infectious complications in a course of multiple myeloma]","volume":"45","author":"Pruchniewski","year":"2018","journal-title":"Pol. Merkur. Lek."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s10787-021-00863-2","article-title":"Bortezomib: A proteasome inhibitor for the treatment of autoimmune diseases","volume":"29","author":"Khalesi","year":"2021","journal-title":"Inflammopharmacology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nrg2489","article-title":"Detecting shared pathogenesis from the shared genetics of immune-related diseases","volume":"10","author":"Zhernakova","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/ijc.24141","article-title":"Autoimmunity and lymphomagenesis","volume":"124","author":"Goldin","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbacli.2016.05.004","article-title":"Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"6","author":"Shimanovsky","year":"2016","journal-title":"BBA Clin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cger.2015.08.012","article-title":"Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults","volume":"32","author":"Guerard","year":"2016","journal-title":"Clin. Geriatr. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","article-title":"Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability","volume":"33","author":"Dutta","year":"2019","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1038\/bcj.2016.123","article-title":"Familial associations of lymphoma and myeloma with autoimmune diseases","volume":"7","author":"Hemminki","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/leu.2016.43","article-title":"Familial associations of monoclonal gammopathy of unknown significance with autoimmune diseases","volume":"30","author":"Hemminki","year":"2016","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/1055-9965.EPI-13-0695","article-title":"Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: A systematic review","volume":"23","author":"McShane","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","article-title":"Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance","volume":"114","author":"Vachon","year":"2009","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood-2010-09-306076","article-title":"Hyperphosphorylated paratarg-7: A new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia","volume":"117","author":"Grass","year":"2011","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1470-2045(09)70331-6","article-title":"Autosomal-dominant inheritance of hyperphosphorylated paratarg-7","volume":"11","author":"Grass","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(09)70234-7","article-title":"Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: A case-control study","volume":"10","author":"Grass","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.clml.2013.08.002","article-title":"Autoimmune neutropenia in multiple myeloma and the role of clonal T-cell expansion: Evidence of cross-talk between B-cell and T-cell lineages?","volume":"14","author":"Aryal","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1111\/ajco.12230","article-title":"Prevalence of autoimmune hemolytic anemia in multiple myeloma: A prospective study","volume":"12","author":"Kashyap","year":"2016","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12288-019-01252-0","article-title":"Autoimmune Hemolytic Anemia as Presenting Manifestation of Multiple Myeloma","volume":"36","author":"Naithani","year":"2020","journal-title":"Indian. J. Hematol. Blood Transfus."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.bjhh.2017.07.005","article-title":"Autoimmune hemolytic anemia and hyperglobulinemia leading to the diagnosis of multiple myeloma","volume":"39","author":"Pacca","year":"2017","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Barcellini, W., Giannotta, J.A., and Fattizzo, B. (2021). Autoimmune Complications in HematologicNeoplasms. Cancers, 13.","DOI":"10.3390\/cancers13071532"},{"key":"ref_35","first-page":"8825618","article-title":"Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature","volume":"2020","author":"Forehand","year":"2020","journal-title":"Case Rep. Hematol."},{"key":"ref_36","first-page":"371","article-title":"Autoimmune cytopenias associated with malignancies and successfully treated with intravenous immune globulins: About two cases","volume":"55","author":"Alliot","year":"2000","journal-title":"Therapie"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13256-020-02505-7","article-title":"Acquired hemophilia A and plasma cell neoplasms: A case report and review of the literature","volume":"14","author":"Jalowiec","year":"2020","journal-title":"J. Med. Case Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/10245332.2017.1319115","article-title":"Acquired hemophilia A: A review of recent data and new therapeutic options","volume":"22","author":"Franchini","year":"2017","journal-title":"Hematology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4274\/tjh.2016.0146","article-title":"Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient","volume":"34","author":"Innao","year":"2017","journal-title":"Turk. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/hae.13355","article-title":"Acquired haemophilia in cancer: A systematic and critical literature review","volume":"24","author":"Napolitano","year":"2018","journal-title":"Haemophilia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0049-0172(97)80029-7","article-title":"Systemic lupus erythematosus and multiple myeloma: A rare association","volume":"26","author":"Afeltra","year":"1997","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e755","DOI":"10.1002\/iid3.755","article-title":"Systemic lupus erythematosus associated with multiple myeloma: Two case reports and a literature review","volume":"11","author":"Lian","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"860794","DOI":"10.3389\/fonc.2022.860794","article-title":"Association Between Systemic Lupus Erythematosus and Cancer Morbidity and Mortality: Findings From Cohort Studies","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1034\/j.1600-065X.2003.00055.x","article-title":"The rise and fall of long-lived humoral immunity: Terminal differentiation of plasma cells in health and disease","volume":"194","author":"Gleeson","year":"2003","journal-title":"Immunol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-017-0464-5","article-title":"Characterization and risk estimate of cancer in patients with primary Sj\u00f6gren syndrome","volume":"10","author":"Kostov","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s002770000166","article-title":"Sj\u00f6gren\u2019s syndrome associated with multiple myeloma","volume":"79","author":"Terpos","year":"2000","journal-title":"Ann. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0929-6646(08)60133-3","article-title":"Primary biliary cirrhosis and IgG-kappa type multiple myeloma both respond well to vincristine, adriamycin and dexamethasone: Is there a pathogenic relationship?","volume":"107","author":"Saka","year":"2008","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4254\/wjh.v7.i7.926","article-title":"Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy","volume":"7","author":"Purohit","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2169\/internalmedicine.32.802","article-title":"Primary biliary cirrhosis associated with multiple myeloma","volume":"32","author":"Kaneko","year":"1993","journal-title":"Intern. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-3-1","article-title":"Primary biliary cirrhosis","volume":"3","author":"Kumagi","year":"2008","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hon.845","article-title":"Review of peripheral neuropathy in plasma cell disorders","volume":"26","author":"Silberman","year":"2008","journal-title":"Hematol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/brain\/118.2.359","article-title":"Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy","volume":"118","author":"Simmons","year":"1995","journal-title":"Brain"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/WCO.0b013e32832fd563","article-title":"Monoclonal gammopathy and neuropathy","volume":"22","author":"Ramchandren","year":"2009","journal-title":"Curr. Opin. Neurol."},{"key":"ref_55","first-page":"e899","article-title":"Multiple Myeloma Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Importance of Continued Surveillance","volume":"8","author":"Fasanya","year":"2016","journal-title":"Cureus"},{"key":"ref_56","first-page":"001360","article-title":"Association of Multiple Myeloma and Giant Cell Arteritis\u2014A Case Report","volume":"7","author":"Pina","year":"2020","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3324\/haematol.10850","article-title":"A VH4-34+ myeloma protein with weak autoreactivity","volume":"92","author":"Thompson","year":"2007","journal-title":"Haematologica"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1359-6101(02)00027-8","article-title":"IL-6 in autoimmune disease and chronic inflammatory proliferative disease","volume":"13","author":"Ishihara","year":"2002","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2174\/156652408786733711","article-title":"The expanding role of APRIL in cancer and immunity","volume":"8","author":"Planelles","year":"2008","journal-title":"Curr. Mol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jdermsci.2015.11.003","article-title":"IL-10-producing regulatory B cells are decreased in patients with psoriasis","volume":"81","author":"Hayashi","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V97.6.1817","article-title":"Interleukin-6 is a growth factor for nonmalignant human plasmablasts","volume":"97","author":"Jego","year":"2001","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863","article-title":"Interleukin-6 in human multiple myeloma","volume":"85","author":"Klein","year":"1995","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/cbir.2000.0497","article-title":"Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma","volume":"24","author":"Hegyesi","year":"2000","journal-title":"Cell Biol. Int."},{"key":"ref_64","first-page":"13","article-title":"Interleukin 6 (IL-6) and its receptor (IL-6R) in myeloma\/plasmacytoma","volume":"166","author":"Suematsu","year":"1990","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/gtmb.2015.0169","article-title":"Association of IL-6 Promoter and Receptor Polymorphisms with Multiple Myeloma Risk: A Systematic Review and Meta-Analysis","volume":"20","author":"Li","year":"2016","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/intimm\/10.11.1703","article-title":"Survival of long-lived plasma cells is independent of antigen","volume":"10","author":"Manz","year":"1998","journal-title":"Int. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coi.2017.03.006","article-title":"Plasma cell and memory B cell differentiation from the germinal center","volume":"45","author":"Suan","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coi.2015.01.017","article-title":"Differentiation and maintenance of long-lived plasma cells","volume":"33","author":"Kometani","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0952-7915(02)00356-4","article-title":"Humoral immunity and long-lived plasma cells","volume":"14","author":"Manz","year":"2002","journal-title":"Curr. Opin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.4049\/jimmunol.169.4.1676","article-title":"Cytokine control of memory B cell homing machinery","volume":"169","author":"Roy","year":"2002","journal-title":"J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1084\/jem.20011626","article-title":"Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population","volume":"195","author":"Cascalho","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/sj.thj.6200313","article-title":"Consequences of interactions between the bone marrow stroma and myeloma","volume":"4","author":"Epstein","year":"2003","journal-title":"Hematol. J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0889-8588(05)70413-5","article-title":"Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma","volume":"11","author":"Teoh","year":"1997","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Allegra, A., Casciaro, M., Barone, P., Musolino, C., and Gangemi, S. (2022). Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma. Cancers, 14.","DOI":"10.3390\/cancers14112597"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF and APRIL: A tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7150\/ijbs.7.651","article-title":"Dual roles of immune cells and their factors in cancer development and progression","volume":"7","author":"Zamarron","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: Back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate Lymphoid Cells: 10 Years On","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2141.1996.4651006.x","article-title":"Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications","volume":"93","author":"Moro","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-230X(08)00407-7","article-title":"IFN inducibility of major histocompatibility antigens in tumors","volume":"101","author":"Seliger","year":"2008","journal-title":"Adv. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/bloodadvances.2017012732","article-title":"Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: Target for IMiD therapy","volume":"1","author":"Mehta","year":"2017","journal-title":"Blood Adv."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Szudy-Szczyrek, A., Ahern, S., Kozio\u0142, M., Majowicz, D., Szczyrek, M., Krawczyk, J., and Hus, M. (2021). Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy. Cancers, 13.","DOI":"10.3390\/cancers13194806"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00281-018-0670-4","article-title":"Innate lymphoid cells in autoimmunity and chronic inflammatory diseases","volume":"40","author":"Xiong","year":"2018","journal-title":"Semin. Immunopathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2013.477","article-title":"Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis","volume":"134","author":"Villanova","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/jid.2014.146","article-title":"Composition of innate lymphoid cell subsets in the human skin: Enrichment of NCR+ ILC3 in lesional skin and blood of psoriasis patients","volume":"134","author":"Teunissen","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/08830185.2020.1736058","article-title":"Advances in applying of multi-omics approaches in the research of systemic lupus erythematosus","volume":"39","author":"Song","year":"2020","journal-title":"Int. Rev. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Ohl, K., and Tenbrock, K. (2011). Inflammatory cytokines in systemic lupus erythematosus. J. Biomed. Biotechnol., 2011.","DOI":"10.1155\/2011\/432595"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1177\/0961203318773643","article-title":"Clinical application of protein biomarkers in lupus erythematosus and lupus nephritis","volume":"27","author":"Qi","year":"2018","journal-title":"Lupus"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0961203311418707","article-title":"1H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus","volume":"20","author":"Ouyang","year":"2011","journal-title":"Lupus"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"149","DOI":"10.12688\/wellcomeopenres.16883.2","article-title":"Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus","volume":"6","author":"Trzupek","year":"2022","journal-title":"Wellcome Open Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1007\/s10238-023-01148-4","article-title":"Multi-omics analysis of multiple myeloma patients with differential response to first-line treatment","volume":"23","author":"Zheng","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders","volume":"111","author":"Brown","year":"2008","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/ard.51.8.951","article-title":"Ankylosing spondylitis and monoclonal gammopathies","volume":"51","author":"Renier","year":"1992","journal-title":"Ann. Rheum. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ajh.20796","article-title":"Multiple myeloma presented as acute interstitial nephritis and rheumatoid arthritis-like polyarthritis","volume":"82","author":"Ardalan","year":"2007","journal-title":"Am. J. Hematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/ejh.13563","article-title":"Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Mellqvist","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0959-8049(93)90188-L","article-title":"Rheumatoid arthritis as a risk factor for multiple myeloma: A case-control study","volume":"29","author":"Eriksson","year":"1993","journal-title":"Eur. J. Cancer."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-8722-5-59","article-title":"Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma","volume":"5","author":"Hemminki","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"103137","DOI":"10.1016\/j.transci.2021.103137","article-title":"Evaluation of patients diagnosed with psoriasis and multiple myeloma after autologous stem cell transplantation","volume":"60","author":"Ugur","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Bartosi\u0144ska, J., Purkot, J., Karczmarczyk, A., Chojnacki, M., Zaleska, J., W\u0142asiuk, P., Grz\u0105\u015bko, N., Morawska, M., Walter-Croneck, A., and Usnarska-Zubkiewicz, L. (2021). Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma. Cells, 10.","DOI":"10.3390\/cells10020411"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/imr.12176","article-title":"B10 cell regulation of health and disease","volume":"259","author":"Candando","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/cei.12949","article-title":"Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1","volume":"188","author":"Bommarito","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"611795","DOI":"10.3389\/fimmu.2021.611795","article-title":"Immunosuppressive Mechanisms of Regulatory B Cells","volume":"12","author":"Mansilla","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.intimp.2018.12.007","article-title":"Regulatory B cells in inflammatory diseases and tumor","volume":"67","author":"Cai","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/cmi.2017.35","article-title":"B cell regulation in cancer and anti-tumor immunity","volume":"14","author":"Sarvaria","year":"2017","journal-title":"Cell Mol. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3892\/or.2016.5291","article-title":"Immature myeloid-derived suppressor cells: A bridge between inflammation and cancer (Review)","volume":"37","author":"Musolino","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1038\/bcj.2017.24","article-title":"Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu","volume":"7","author":"Zhang","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/0008-5472.CAN-14-3639","article-title":"CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer","volume":"75","author":"Karakasheva","year":"2015","journal-title":"Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Whitehill","year":"2013","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/eji.201040673","article-title":"IL-10 produced by activated human B cells regulates CD4+ T-cell activation in vitro","volume":"40","author":"Bouaziz","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_112","first-page":"173ra23","article-title":"CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation","volume":"5","author":"Bosma","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1002\/art.38666","article-title":"Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity","volume":"66","author":"Daien","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.immuni.2009.11.009","article-title":"CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients","volume":"32","author":"Blair","year":"2010","journal-title":"Immunity"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.13840","article-title":"Treatment horizon in multiple myeloma","volume":"109","author":"Soekojo","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: A first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e003464","DOI":"10.1136\/rmdopen-2023-003464","article-title":"Efficacy of daratumumab in refractory primary Sj\u00f6gren disease","volume":"9","author":"Nocturne","year":"2023","journal-title":"RMD Open"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumabmonotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.berh.2017.10.003","article-title":"Role of interferons in SLE","volume":"31","author":"Bengtsson","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000330067","article-title":"Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models","volume":"88","author":"Tung","year":"2011","journal-title":"Pharmacology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.critrevonc.2014.05.003","article-title":"Linking the activity of bortezomib in multiple myeloma and autoimmune diseases","volume":"92","author":"Cvek","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17474086.2016.1216311","article-title":"The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders","volume":"9","author":"Citrin","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3109\/10428194.2014.914203","article-title":"Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: Selective occurrence after lenalidomide","volume":"55","author":"Montefusco","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JCO.2006.08.4053","article-title":"Lenalidomide-induced warm autoimmune hemolytic anemia","volume":"24","author":"Darabi","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2182619","DOI":"10.1080\/09546634.2023.2182619","article-title":"Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma","volume":"34","author":"Mioso","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1200\/JCO.2008.17.6560","article-title":"Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma","volume":"26","author":"Braiteh","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1532\/IJH97.06029","article-title":"Recurrence of autoimmune disease after autologous peripheral blood stem cell transplantation for multiple myeloma","volume":"84","author":"Isshiki","year":"2006","journal-title":"Int. J. Hematol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/1078155220927750","article-title":"Coincident remission of ankylosing spondylitis after autologous stem cell transplantation for multiple myeloma","volume":"27","author":"Shaikh","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/imcb.12390","article-title":"Systemic administration of IL-33 induces a population of circulating KLRG1hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma","volume":"99","author":"Guillerey","year":"2021","journal-title":"Immunol. Cell Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.12146","article-title":"Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease","volume":"160","author":"Musolino","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-012-0008-z","article-title":"Bispecific antibodies and trispecificimmunocytokines for targeting the immune system against cancer: Preparing for the future","volume":"27","author":"Fournier","year":"2013","journal-title":"BioDrugs"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40259-018-0299-9","article-title":"Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies","volume":"32","author":"Husain","year":"2018","journal-title":"BioDrugs"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40259-019-00400-2","article-title":"Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date","volume":"34","author":"Zhao","year":"2020","journal-title":"BioDrugs"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/11\/1135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:50:36Z","timestamp":1760107836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/11\/1135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":141,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["diagnostics14111135"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14111135","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}